ClinicalTrials.gg
CompletedNCT04828005Updated Jul 14, 2025Results posted

Pharmacodynamic Evaluation of Intranasal Nalmefene

A Phase 1 interventional study of Nalmefene hydrochloride and Naloxone hydrochloride in Pharmacodynamic, sponsored by Opiant Pharmaceuticals Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Opiant Pharmaceuticals Inc (part of Indivior Pharmaceuticals, Inc.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is to determine the pharmacodynamics (the effects of the drug and mechanisms of their action within the body) of Nalmefene when given intranasally (IN; into the nose) compared to intranasal naloxone when given to healthy volunteers under steady state opioid agonism.

Read the detailed description

Open-label, 2-part study. Part 1 is a pilot study to determine the relationship between opioid agonism and suppression of carbon dioxide induced increases in minute ventilation prior to opioid exposure. Part 2 will be a randomized, 2 period, 2 treatment, crossover study to evaluate the pharmacodynamic effects of intranasal (IN) nalmefene compared to IN naloxone to reverse opioid-induced suppression of carbon dioxide induced increases in minute ventilation, in healthy volunteers with prior opioid exposure.

Both Part 1 and Part 2 of the study will consist of an outpatient Screening Visit taking place 28 days prior to admission, an in-clinic Treatment Phase consisting of a 6 or 7 day inpatient stay, and a Follow-Up Phone Call conducted 3 to 7 days after discharge.

02

Conditions studied

  • Pharmacodynamic
03

In context

Lead sponsor

Opiant Pharmaceuticals Inc is the lead sponsor of 3 studies on the registry; none are open to participants now.

First submitted before Opiant Pharmaceuticals Inc became part of Indivior Pharmaceuticals, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 55 years inclusive
  • ranging from 18 to 32 kg/m2, inclusive
  • Adequate venous access
  • Healthy subjects and non-dependent who are non dependent opioid experienced users, opioid experience defined as exposure to an opioid on at least 1 occasion prior to screening

Exclusion criteria

Exclusion Criteria:

  • History of disease
  • Significant trauma injury, major surgery, open within 30 days prior to screening
  • Subject who has a difficult airway for intubation.
  • Following an abnormal diet 4 weeks prior to screening
  • Use of over-the-counter medications, dietary supplements, herbal products, vitamins or opioid analgesics 14 days before intervention
  • Use of enzyme altering drugs 30 days before intervention
  • Use of nasal products 28 days before intervention and throughout the study
  • Previous or current opioid, alcohol, or other drug dependence
  • Donated or received blood 30 days before intervention
  • Women who are pregnant or breastfeeding at screening
  • Women of unless surgically sterile or use effective
  • Current or recent upper respiratory tract infection
  • Allergic to nalmefene or naloxone or known reaction to plastics.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Intranasal Nalmefene

    Nalmefene hydrochloride nasal spray, 3mg, 1 spray

    Drug: Nalmefene hydrochloride

  • Active comparator
    Intranasal Naloxone

    Naloxone hydrochloride nasal spray, 4mg, 1 spray

    Drug: Naloxone hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Minute Ventilation

    Change in minute ventilation from opioid induced nadir

    Time frame: 5 minutes

Secondary outcomes

  1. Maximum Change in Minute Ventilation

    Maximum change in minute ventilation from opioid induced nadir

    Time frame: Up to 2 hours

  2. Time to Maximum Change in Minute Ventilation

    Time to maximum change in minute ventilation from opioid induced nadir

    Time frame: Up to 2 hours

  3. Change in Minute Ventilation

    Change in minute ventilation from opioid induced nadir

    Time frame: 90 minutes

  4. Change in Minute Ventilation

    Change in minute ventilation from opioid induced nadir

    Time frame: 20 minutes

  5. Change in Minute Ventilation

    Change in minute ventilation from opioid induced nadir

    Time frame: 15 minutes

  6. Change in Minute Ventilation

    Change in minute ventilation from opioid induced nadir

    Time frame: 10 minutes

  7. Change in Minute Ventilation

    Change in minute ventilation from opioid induced nadir

    Time frame: 2.5 minutes

07

Results

Posted Jul 14, 2025

Participant flow

Part 1 Setup: 1st Treatment (1 Day)
Participant flow — Part 1 Setup: 1st Treatment (1 Day)
MilestonePart 1 Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 2: Intranasal Nalmefene Crossover to Intranasal NaloxonePart 2: Intranasal Naloxone Crossover to Intranasal Nalmefene
Started7000
Completed7000
Not completed0000
Part 1 Setup: Washout (4 Days)
Participant flow — Part 1 Setup: Washout (4 Days)
MilestonePart 1 Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 2: Intranasal Nalmefene Crossover to Intranasal NaloxonePart 2: Intranasal Naloxone Crossover to Intranasal Nalmefene
Started7000
Completed5000
Not completed2000
Withdrew: Withdrawal by subject2000
Part 1 Setup: 2nd Treatment (1 Day)
Participant flow — Part 1 Setup: 2nd Treatment (1 Day)
MilestonePart 1 Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 2: Intranasal Nalmefene Crossover to Intranasal NaloxonePart 2: Intranasal Naloxone Crossover to Intranasal Nalmefene
Started5000
Completed5000
Not completed0000
Part 1 Extension: 1st Treatment (1 Day)
Participant flow — Part 1 Extension: 1st Treatment (1 Day)
MilestonePart 1 Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 2: Intranasal Nalmefene Crossover to Intranasal NaloxonePart 2: Intranasal Naloxone Crossover to Intranasal Nalmefene
Started0800
Completed0800
Not completed0000
Part 2: 1st Treatment (1 Day)
Participant flow — Part 2: 1st Treatment (1 Day)
MilestonePart 1 Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 2: Intranasal Nalmefene Crossover to Intranasal NaloxonePart 2: Intranasal Naloxone Crossover to Intranasal Nalmefene
Started003435
Completed002732
Not completed0073
Withdrew: Withdrawal by subject0021
Withdrew: Adverse event0030
Withdrew: Protocol violation0021
Withdrew: Equipment failure0001
Part 2: Washout (4 Days)
Participant flow — Part 2: Washout (4 Days)
MilestonePart 1 Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 2: Intranasal Nalmefene Crossover to Intranasal NaloxonePart 2: Intranasal Naloxone Crossover to Intranasal Nalmefene
Started002732
Completed002530
Not completed0022
Withdrew: Withdrawal by subject0020
Withdrew: Physician decision0002
Part 2: 2nd Treatment (1 Day)
Participant flow — Part 2: 2nd Treatment (1 Day)
MilestonePart 1 Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal NaloxonePart 2: Intranasal Nalmefene Crossover to Intranasal NaloxonePart 2: Intranasal Naloxone Crossover to Intranasal Nalmefene
Started002530
Completed002527
Not completed0003
Withdrew: Protocol violation0002
Withdrew: Adverse event0001

Outcome measures

PrimaryChange in Minute Ventilation

Change in minute ventilation from opioid induced nadir

Time frame:
5 minutes
Reported as:
Mean · L/min
Change in Minute Ventilation
L/minIntranasal NaloxoneIntranasal Nalmefene
Change in Minute Ventilation3.432 ± 0.61175.744 ± 0.6240
Statistical analysis
  • Intranasal Naloxone · Mixed Models Analysis · p = <0.0009
SecondaryMaximum Change in Minute Ventilation

Maximum change in minute ventilation from opioid induced nadir

Time frame:
Up to 2 hours
Reported as:
Mean · ng/mL
Maximum Change in Minute Ventilation
ng/mLIntranasal NalmefeneIntranasal Naloxone
Maximum Change in Minute Ventilation6.8 ± 2.75.8 ± 3.0
SecondaryTime to Maximum Change in Minute Ventilation

Time to maximum change in minute ventilation from opioid induced nadir

Time frame:
Up to 2 hours
Reported as:
Median · hour
Time to Maximum Change in Minute Ventilation
hourIntranasal NalmefeneIntranasal Naloxone
Time to Maximum Change in Minute Ventilation0.50 (0.04 to 2.00)0.75 (0.13 to 2.00)
SecondaryChange in Minute Ventilation

Change in minute ventilation from opioid induced nadir

Time frame:
90 minutes
Reported as:
Mean · L/min
Change in Minute Ventilation
L/minIntranasal NalmefeneIntranasal Naloxone
Change in Minute Ventilation2.71 ± 0.592.14 ± 0.62
SecondaryChange in Minute Ventilation

Change in minute ventilation from opioid induced nadir

Time frame:
20 minutes
Reported as:
Mean · L/min
Change in Minute Ventilation
L/minIntranasal NalmefeneIntranasal Naloxone
Change in Minute Ventilation6.79 ± 0.715.93 ± 0.68
SecondaryChange in Minute Ventilation

Change in minute ventilation from opioid induced nadir

Time frame:
15 minutes
Reported as:
Mean · L/min
Change in Minute Ventilation
L/minIntranasal NalmefeneIntranasal Naloxone
Change in Minute Ventilation7.12 ± 0.775.55 ± 0.64
SecondaryChange in Minute Ventilation

Change in minute ventilation from opioid induced nadir

Time frame:
10 minutes
Reported as:
Mean · L/min
Change in Minute Ventilation
L/minIntranasal NalmefeneIntranasal Naloxone
Change in Minute Ventilation6.58 ± 0.664.96 ± 0.69
SecondaryChange in Minute Ventilation

Change in minute ventilation from opioid induced nadir

Time frame:
2.5 minutes
Reported as:
Mean · L/min
Change in Minute Ventilation
L/minIntranasal NalmefeneIntranasal Naloxone
Change in Minute Ventilation2.55 ± 0.381.71 ± 0.53

Adverse events

Collected over Crossover study adverse event data collected form baseline through to day 6 with a +3 to 7 day follow-up. During the 6 day dosing they took either nalmefene or naloxone on day 1 followed by a 3 day washout and the other dose on day 5. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intranasal Nalmefene0/61 (0%)0/61 (0%)56/61 (91.8%)
Intranasal Naloxone0/60 (0%)0/60 (0%)52/60 (86.7%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventIntranasal NalmefeneIntranasal Naloxone
HeadacheNervous system disorders36/6135/60
NauseaGastrointestinal disorders24/6125/60
VomitingGastrointestinal disorders7/6114/60
Hot FlushVascular disorders14/617/60
DizzinessNervous system disorders11/6113/60
AnxietyPsychiatric disorders10/614/60
FatigueGeneral disorders6/612/60
DysgeusiaNervous system disorders2/615/60
Nasal discomfortRespiratory, thoracic and mediastinal disorders5/610/60
SomnolenceNervous system disorders2/614/60

Baseline characteristics

Age, Customized
Age, Customized(years)Part 1: Intranasal NalmefenePart 1 Extension: Intranasal NalmefenePart 2: Intranasal Nalmefene Compared to Intranasal NaloxoneTotal
Mean28.6 ± 4.5029.1 ± 11.0529.1 ± 7.7929.1 ± 7.84
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Intranasal NalmefenePart 1 Extension: Intranasal NalmefenePart 2: Intranasal Nalmefene Compared to Intranasal NaloxoneTotal
Female122124
Male664860
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Intranasal NalmefenePart 1 Extension: Intranasal NalmefenePart 2: Intranasal Nalmefene Compared to Intranasal NaloxoneTotal
White665769
Black or African American1269
Asian0022
American Indian or Alaskan Native0033
Native Hawaiian or Other Pacific Islander0011
Not Reported0000
Unknown0000
Region of Enrollment
Region of Enrollment(participants)Part 1: Intranasal NalmefenePart 1 Extension: Intranasal NalmefenePart 2: Intranasal Nalmefene Compared to Intranasal NaloxoneTotal
United States786984
BMI
BMI(kg/m2)Part 1: Intranasal NalmefenePart 1 Extension: Intranasal NalmefenePart 2: Intranasal Nalmefene Compared to Intranasal NaloxoneTotal
Mean25.03 ± 3.33824.48 ± 3.66525.27 ± 3.31625.17 ± 3.317
Weight
Weight(kg)Part 1: Intranasal NalmefenePart 1 Extension: Intranasal NalmefenePart 2: Intranasal Nalmefene Compared to Intranasal NaloxoneTotal
Mean79.13 ± 16.61678.65 ± 9.73578.30 ± 14.12078.40 ± 13.833
Height
Height(cm)Part 1: Intranasal NalmefenePart 1 Extension: Intranasal NalmefenePart 2: Intranasal Nalmefene Compared to Intranasal NaloxoneTotal
Mean178.7 ± 9.71179.8 ± 9.38175.6 ± 10.21176.3 ± 10.08
08

Study locations

1 site
  • PRA Health Sciences
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Mar 2022, 11 months.

Results were first posted in Jul 2025, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2021
First posted
Apr 1, 2021
StartActual
Mar 30, 2021
Primary completionActual
Mar 14, 2022
CompletionActual
Mar 14, 2022
Results first posted
Jul 14, 2025
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04828005
Responsible party
Sponsor
First posted
Apr 1, 2021
Start date
Mar 30, 2021
Primary completion
Mar 14, 2022
Completion
Mar 14, 2022
Results posted
Jul 14, 2025
Last update
Jul 14, 2025

Study contacts

Shawn Searle, MD
principal investigator · PRA Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion